CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

An FDA panel of experts has recommended approval of Pfizer’s respiratory syncytial virus (RSV) vaccine in a pair of ... s RSVPreF3 jab will come under the scrutiny of the VRBPAC later today ...

The advisory panel to the Centers for Disease Control and Prevention had made recommendations regarding the use of separate ...

Pfizer (PFE) stock draws public scrutiny as a House probe gathers new allegations regarding the company's COVID-19 vaccine ...

GSK's vaccine against respiratory syncytial virus (RSV) is one of ... with the final results of Pfizer's study and as the data from both studies is subjected to scrutiny. The two companies say ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) has issued new separate recommendations supporting expanded use of Pfizer’s respiratory syncytial ...

The advisory committee meeting is an important step in the process of readying boosters for the fall and winter season, but ...

Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and older, and adults 18 and older at increased risk of lower respiratory tract disease caused by RSV (RSV ...

Pfizer recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline ...